Prognostic factors of early mortality in children and adolescents with relapsed/refractory solid tumors participating in dose-finding trials in the targeted and immune therapies era: An ITCC study
European Journal of Cancer · 2025
DOI: 10.1016/j.ejca.2025.115627 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Cancer, 2025. Verfasst von Fernando Carceller und 36 weiteren Autor:innen. Beteiligte Einrichtung: Children & Young People's Unit, The Royal Marsden NHS Foundation Trust, London, UK; Division of Clinical Studies, The Institute of Cancer Research, L…. Hauptthemen laut MEDLINE: Neoplasms, Neoplasm Recurrence, Local, Immunotherapy. Die Arbeit nennt 21 Literaturangaben. Gefördert von: Royal Marsden Cancer Charity, Institute of Cancer Research, NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Children & Young People's Unit, The Royal Marsden NHS Foundation Trust, London, UK; Division of Clinical Studies, The Institute of Cancer Research, London, UK. Electronic address: fernando.carceller@icr.ac.uk.
- Department of Pediatric and Adolescent Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France; Department of Pediatric Oncology, Hematology and Stem Cell Transplantation, Hospital Niño Jesús, Madrid, Spain…
- Prinses Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
- Department of Pediatric and Adolescent Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
- SIREDO, Institut Curie, Paris, France.
- Children & Young People's Unit, The Royal Marsden NHS Foundation Trust, London, UK.
Förderung
- Royal Marsden Cancer Charity
- Institute of Cancer Research
- NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research
- Associazione Italiana per la Lotta al Neuroblastoma
- National Institute for Health and Care Research
- Carlos III Health Institute
- NIHR Great Ormond Street Hospital Biomedical Research Centre
- Institut National Du Cancer
Zitieren
APA
Carceller, F., Bautista, F., Van Tinteren, H., Castañeda, A., Surun, A., Wasti, A., Revon-Rivière, G., Bergamaschi, L., Cortés, M., Hladun-Álvaro, R., Jiménez, I., Giraud, C., Millen, G., Campbell-Hewson, Q., Juan-Ribelles, A., Van der Lugt, J., Amoroso, L., Bertorello, N., Hargrave, D., …, & Moreno, L. (2025). Prognostic factors of early mortality in children and adolescents with relapsed/refractory solid tumors participating in dose-finding trials in the targeted and immune therapies era: An ITCC study. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2025.115627
Vancouver
Carceller F, Bautista F, Van Tinteren H, Castañeda A, Surun A, Wasti A, et al. Prognostic factors of early mortality in children and adolescents with relapsed/refractory solid tumors participating in dose-finding trials in the targeted and immune therapies era: An ITCC study. European Journal of Cancer. 2025. doi:10.1016/j.ejca.2025.115627
BibTeX
@article{Carceller2025,
author = {Carceller, Fernando and Bautista, Francisco and Van Tinteren, Harm and Castañeda, Alicia and Surun, Aurore and Wasti, Ajla and Revon-Rivière, Gabriel and Bergamaschi, Luca and Cortés, Marta and Hladun-Álvaro, Raquel and Jiménez, Irene and Giraud, Cécile and Millen, Gerard and Campbell-Hewson, Quentin and Juan-Ribelles, Antonio and Van der Lugt, Jasper and Amoroso, Loredana and Bertorello, Nicoletta and Hargrave, Darren and Vega-Piris, Lorena and Fagioli, Franca and Haupt, Riccardo and Zwaan, C Michel and Cañete, Adela and Morland, Bruce and Ceraulo, Antony and Casanova, Michela and Verschuur, Arnauld and André, Nicolas and Aerts, Isabelle and Doz, François and Pearson, Andrew D J and Marshall, Lynley V and Vassal, Gilles and Kearns, Pamela and Geoerger, Birgit and Moreno, Lucas},
title = {Prognostic factors of early mortality in children and adolescents with relapsed/refractory solid tumors participating in dose-finding trials in the targeted and immune therapies era: An ITCC study},
journal = {European Journal of Cancer},
year = {2025},
doi = {10.1016/j.ejca.2025.115627}
}
EUVIMED